Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Raises $2.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NanoString Technologies has raised $2.5 million of a targeted $14 million round.

In an e-mail, Brad Gray, CEO of the Seattle-based life science firm, said that the funding comes from its current major investors and will be used to grow the company. He declined further comment.

In January, Gray told GenomeWeb Daily News that NanoString is looking to build its diagnostics business, with an emphasis on the molecular diagnostics space.

According to a document filed with the US Securities and Exchange Commission filed on June 29, the securities in the current offering are in the form of debt; options, warrants, or other rights to acquire another security; security to be acquire upon exercise of options, warrants, or other rights to acquire security.

In December, NanoString announced it had acquired the worldwide rights to technology from Bioclassifier, a partnership of four breast cancer experts from four research institutions, to develop in vitro diagnostic and research products for breast cancer intrinsic subtyping.

Two years ago, the firm raised $30 million in a Series C round.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.